Clinuvel Pharmaceuticals (OTCMKTS:CLVLY) Trading Down 3.5% – Should You Sell?

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) dropped 3.5% during trading on Tuesday . The stock traded as low as $7.01 and last traded at $7.10. 3,500 shares traded hands during trading, an increase of 29% from the average session volume of 2,714 shares. The stock had previously closed at $7.36.

Clinuvel Pharmaceuticals Price Performance

The stock has a 50-day moving average of $6.70 and a two-hundred day moving average of $7.40.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.

The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.